Group 1 - The company Guangxi Wuzhou Zhongheng Group Co., Ltd. announced that its subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for procurement [1][2] - The selected products are projected to generate a total sales revenue of 106.19 million yuan in 2024, accounting for 4.68% of the company's total revenue for that year. For the first three quarters of 2025, the expected sales revenue is 66.07 million yuan, representing 3.39% of the company's revenue for that period [1][2] Group 2 - The procurement is organized by a national alliance consisting of various provinces and regions, with Jiangsu, Henan, and Guangdong provinces leading the initiative. The procurement aims to ensure that medical institutions prioritize the selected products, which is expected to enhance sales and market expansion for the company [2]